TLDR Home Depot beat Wall Street’s Q4 earnings and revenue expectations with EPS of $2.72 vs. $2.54 expected and revenue of $38.20B vs. $38.12B expected Q4 salesTLDR Home Depot beat Wall Street’s Q4 earnings and revenue expectations with EPS of $2.72 vs. $2.54 expected and revenue of $38.20B vs. $38.12B expected Q4 sales

Home Depot (HD) Stock Beats Q4 Estimates Despite Sales Drop

2026/02/24 19:14
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

TLDR

  • Home Depot beat Wall Street’s Q4 earnings and revenue expectations with EPS of $2.72 vs. $2.54 expected and revenue of $38.20B vs. $38.12B expected
  • Q4 sales dropped 3.8% year-over-year, partly due to one fewer week in the fiscal calendar
  • The company raised its quarterly dividend 1.3% to $2.33 per share — its 156th consecutive quarterly dividend
  • CFO Richard McPhail cited a “frozen housing environment” lasting three years and growing consumer uncertainty
  • Home Depot guided fiscal 2026 for total sales growth of 2.5%–4.5% and is still evaluating the impact of Trump’s proposed 15% across-the-board tariff

Home Depot posted its Q4 fiscal 2025 results on Tuesday, beating Wall Street’s earnings and revenue estimates despite a drop in total sales.

Adjusted EPS came in at $2.72, topping the $2.54 analysts expected. Revenue hit $38.20 billion, just above the $38.12 billion consensus. It was the first earnings beat after missing estimates three quarters in a row.

Total sales fell 3.8% from the same quarter last year, dropping from $39.70 billion to $38.20 billion. The company said roughly $2.5 billion of that decline is explained by the prior year’s quarter having 14 weeks versus 13 weeks this time around.


HD Stock Card
The Home Depot, Inc., HD

Comparable sales — which strip out factors like store openings — rose 0.4% for the overall business and 0.3% in the U.S.

Net income for the quarter came in at $2.57 billion, or $2.58 per diluted share, down from $3.0 billion, or $3.02 per share, in the year-ago period.

Store transaction volume fell 1.6% year-over-year, but average ticket size rose 2.4%. Big-ticket purchases — those over $1,000 — were up 1.3%.

Pro Segment Picks Up the Slack

While do-it-yourself customers have pulled back on spending, the Pro segment held up better. McPhail confirmed Pro sales outpaced DIY in Q4, though he didn’t give specific numbers.

The company leaned into that trend through acquisitions. It bought SRS Distribution for $18.25 billion in 2024 and followed that with the purchase of GMS, a specialty building products distributor, for about $4.3 billion.

Home Depot opened 12 stores in fiscal 2025 and plans to add 15 more this fiscal year. It currently operates 2,359 retail stores and over 1,250 SRS locations.

Tariffs and Dividends in Focus

The company raised its quarterly dividend by 1.3% to $2.33 per share — marking the 156th consecutive quarter it has paid a cash dividend. The dividend is payable March 26, 2026, to shareholders of record as of March 12, 2026.

On tariffs, McPhail said the company is still working through the numbers following the Supreme Court ruling that struck down parts of the Trump administration’s import duties. President Trump has since proposed a 15% across-the-board global tariff.

For fiscal 2026, Home Depot guided for total sales growth of 2.5% to 4.5%, comparable sales growth of flat to 2%, and adjusted EPS growth of flat to 4% from the $14.69 base in fiscal 2025.

The average rate on a 30-year fixed mortgage fell to 5.99% on Monday — its lowest level since 2022, per Mortgage News Daily.

The post Home Depot (HD) Stock Beats Q4 Estimates Despite Sales Drop appeared first on CoinCentral.

Market Opportunity
Ucan fix life in1day Logo
Ucan fix life in1day Price(1)
$0.0004868
$0.0004868$0.0004868
-6.65%
USD
Ucan fix life in1day (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09